blastic plasmacytoid dendritic cell neoplasm
Haematology · 2023–2023
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tagraxofusp First-line treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients who have not received prior systemic therapy. | Jul 2023 | Not recommended | input received Rare Cancers Australia |
Who spoke
Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.